Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/4/2017
SIETES contiene 91761 citas

 
 
 1 a 20 de 2078 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Rilpivirine et HIV chez les adolescents. Prescrire 2017;37:13-4. [Ref.ID 101362]
3. Cita con resumen
5.Enlace a cita original
Kaguelidou F, Beau-Salinas F, Jonville-Bera AP, Jacqz-Aigrain E. Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database. Br J Clin Pharmacol 2016;82:1058-68. [Ref.ID 100828]
6. Cita con resumen
Anónimo. Elvitegravir (Vitekta) for HIV. Med Lett Drugs Ther 2016;58:10-1. [Ref.ID 100789]
7.Enlace a cita original
Günthard HF, Saag MS, Benson CA, Del Río C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society - USA Panel. JAMA 2016;316:191-210. [Ref.ID 100629]
8. Cita con resumen
Anónimo. UK court rules that NHS can fund HIV PrEP drug. DIA Daily 2016:1. [Ref.ID 100564]
9. Cita con resumen
Anónimo. Loperamide (Imodium): Drug Safety Communication - Serious heart problems with high doses from abuse and misuse. FDA U.S. Food and Drug Administration 2016:7 de junio. [Ref.ID 100377]
11. Cita con resumen
Anónimo. QT interval and drug therapy. Drug Ther Bull 2016;54:33-6. [Ref.ID 100134]
12. Cita con resumen
Anónimo. India adds 28 new drugs to essential medicines list. DIA Daily 2015:28 de diciembre. [Ref.ID 99744]
13. Cita con resumen
Anónimo. Hyponatrémies d'origine médicamenteuse. Prescrire 2015;35:666-71. [Ref.ID 99717]
14.Tiene citas relacionadas Cita con resumen
Anónimo. Darunavir + cobicistat. Prescrire 2015;35:649. [Ref.ID 99709]
15.Tiene citas relacionadas Cita con resumen
Anónimo. Cobicistat. Prescrire 2015;35:648-9. [Ref.ID 99708]
16.Tiene citas relacionadas Cita con resumen
Ko TM, Tsai CY, Chen S-Y, Chen KS, Yu K-H, Chu C-S, Huang CM, Wang CR, Weng C-T, Yu C-L, Hsieh S-C, Tsai J-C, Lai W-T, Tsai W-C, Yin G-D, Ou T-T, Cheng K-H, Yen J-H, Liou T-L, Lin T-H, Chen D-Y, Hsiao P-J, Chen DY, Weng M-Y, Chen Y-M, Chen C-H, Liu F-M, Yen H-W, Lee J-J, Hung S-Y, Luo S-F, Yang Y-H, Chuang H-P, Chou Y-C, Liao H-T, Wang C-W, Huang C-L, Chen P, Wong C-S, Wu J-Y, Chen Y-T, Shen C-Y, for the Taiwan Allopurinol-SCAR Consortium. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ 2015;351:h4848. [Ref.ID 99587]
17.Tiene citas relacionadas Cita con resumen
Li-Wan-Po A. Pharmacogenetics begins to deliver on its promises. BMJ 2015;351:h5042. [Ref.ID 99584]
18.Enlace a cita original Cita con resumen
Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P, for the ALLY-2 Investigators. Daclastavir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:714-25. [Ref.ID 99507]
19.Enlace a cita original Cita con resumen
Naggie S, Cooper C, Saag M, Workowski K, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CAM, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M, for the ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705-13. [Ref.ID 99506]
20. Cita con resumen
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S, GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015;385:2606-15. [Ref.ID 99315]
Seleccionar todas
 
 1 a 20 de 2078 siguiente >>